Hyperglycemia-induced endothelial
inflammation participates in the pathogenesis of cardiovascular complications in diabetics. Previous studies showed that
protein tyrosine phosphatase 1B (PTP1B) and ETS proto-oncogene 1 (ets1) are involved in
hyperglycemia-induced endothelial
inflammation. In this study, we hypothesized that ets1 modulates PTP1B expression, thus playing a crucial role in
hyperglycemia-induced vascular endothelial
inflammation. Our results indicated that high
glucose increases monocyte/endothelial adhesion,
vascular cell adhesion molecule-1 (VCAM-1) expression and p65 phosphorylation in human umbilical vein endothelial cells (HUVECs). Moreover, high
glucose-mediated endothelial
inflammation is reversed by PTP1B silencing. In addition, high
glucose increases ets1 expression in HUVECs. silencing reverses high
glucose-mediated endothelial
inflammation. Furthermore, the effect of ets1 overexpression is similar to that of high
glucose treatment, which is counteracted by si-PTP1B. The results from ChIP assays indicated that ets1 occupies the PTP1B promoter region. Ets1 overexpression enhances PTP1B promoter activity, which is disappeared after specific binding site mutation. experiments demonstrated that the expressions of
VCAM-1, PTP1B, and ets1, as well as the phosphorylation of p65 are augmented in the aorta of diabetic rats. In conclusion, ets1 contributes to
hyperglycemia-mediated endothelial
inflammation via upregulation of PTP1B expression.